Bristol-Myers Squibb in integrity agreement as part of settlement

Share this article:

Bristol-Myers Squibb (BMS) has entered into a corporate integrity agreement (CIA) with the Office of Inspector General of the Department of Health and Human Services as part of a civil settlement to resolve allegations that the company inflated its drug prices and was involved in kickbacks to doctors.

Under the terms of the CIA, the drugmaker will be required to report its average sales prices and average manufacturer prices for drugs covered by Medicare and other federal health care programs for a five-year term.

Among the other obligations contained in the 80-page CIA are the continued development and maintenance of the company's compliance programs related to its US pharmaceuticals business.

The terms of the integrity agreement will not affect BMS' ongoing business with customers or the government, the drugmaker said in a statement.

Additional terms of the civil settlement require BMS to pay $515 million in penalties.

There were no criminal charges filed against the company.

 

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...